Tags

Type your tag names separated by a space and hit enter

Focus on FKBP51: A molecular link between stress and metabolic disorders.
Mol Metab. 2019 11; 29:170-181.MM

Abstract

BACKGROUND

Obesity, Type 2 diabetes (T2D) as well as stress-related disorders are rising public health threats and major burdens for modern society. Chronic stress and depression are highly associated with symptoms of the metabolic syndrome, but the molecular link is still not fully understood. Furthermore, therapies tackling these biological disorders are still lacking. The identification of shared molecular targets underlying both pathophysiologies may lead to the development of new treatments. The FK506 binding protein 51 (FKBP51) has recently been identified as a promising therapeutic target for stress-related psychiatric disorders and obesity-related metabolic outcomes.

SCOPE OF THE REVIEW

The aim of this review is to summarize current evidence of in vitro, preclinical, and human studies on the stress responsive protein FKBP51, focusing on its newly discovered role in metabolism. Also, we highlight the therapeutic potential of FKBP51 as a new treatment target for symptoms of the metabolic syndrome.

MAJOR CONCLUSIONS

We conclude the review by emphasizing missing knowledge gaps that remain and future research opportunities needed to implement FKBP51 as a drug target for stress-related obesity or T2D.

Authors+Show Affiliations

Research Group Neurobiology of Stress Resilience, Max Planck Institute of Psychiatry, 80804, Munich, Germany. Electronic address: alexander.haeusl@biophyll.com.Hotchkiss Brain Institute, University of Calgary, 3330 Hospital Drive NW, Calgary, Ab T2N 4N1, Canada.Department of Psychiatry and Psychotherapy, Bonn Clinical Center, University of Bonn, 53127, Bonn, Germany; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804, Munich, Germany.Research Group Neurobiology of Stress Resilience, Max Planck Institute of Psychiatry, 80804, Munich, Germany. Electronic address: mschmidt@psych.mpg.de.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

31668388

Citation

Häusl, Alexander S., et al. "Focus On FKBP51: a Molecular Link Between Stress and Metabolic Disorders." Molecular Metabolism, vol. 29, 2019, pp. 170-181.
Häusl AS, Balsevich G, Gassen NC, et al. Focus on FKBP51: A molecular link between stress and metabolic disorders. Mol Metab. 2019;29:170-181.
Häusl, A. S., Balsevich, G., Gassen, N. C., & Schmidt, M. V. (2019). Focus on FKBP51: A molecular link between stress and metabolic disorders. Molecular Metabolism, 29, 170-181. https://doi.org/10.1016/j.molmet.2019.09.003
Häusl AS, et al. Focus On FKBP51: a Molecular Link Between Stress and Metabolic Disorders. Mol Metab. 2019;29:170-181. PubMed PMID: 31668388.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Focus on FKBP51: A molecular link between stress and metabolic disorders. AU - Häusl,Alexander S, AU - Balsevich,Georgia, AU - Gassen,Nils C, AU - Schmidt,Mathias V, Y1 - 2019/09/11/ PY - 2019/07/04/received PY - 2019/09/03/revised PY - 2019/09/05/accepted PY - 2019/11/1/entrez PY - 2019/11/2/pubmed PY - 2020/5/27/medline KW - Adipogensis KW - FKBP51 KW - Glucose uptake KW - Obesity KW - SAFit2 KW - Stress KW - Type 2 diabetes SP - 170 EP - 181 JF - Molecular metabolism JO - Mol Metab VL - 29 N2 - BACKGROUND: Obesity, Type 2 diabetes (T2D) as well as stress-related disorders are rising public health threats and major burdens for modern society. Chronic stress and depression are highly associated with symptoms of the metabolic syndrome, but the molecular link is still not fully understood. Furthermore, therapies tackling these biological disorders are still lacking. The identification of shared molecular targets underlying both pathophysiologies may lead to the development of new treatments. The FK506 binding protein 51 (FKBP51) has recently been identified as a promising therapeutic target for stress-related psychiatric disorders and obesity-related metabolic outcomes. SCOPE OF THE REVIEW: The aim of this review is to summarize current evidence of in vitro, preclinical, and human studies on the stress responsive protein FKBP51, focusing on its newly discovered role in metabolism. Also, we highlight the therapeutic potential of FKBP51 as a new treatment target for symptoms of the metabolic syndrome. MAJOR CONCLUSIONS: We conclude the review by emphasizing missing knowledge gaps that remain and future research opportunities needed to implement FKBP51 as a drug target for stress-related obesity or T2D. SN - 2212-8778 UR - https://www.unboundmedicine.com/medline/citation/31668388/Focus_on_FKBP51:_A_molecular_link_between_stress_and_metabolic_disorders_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2212-8778(19)30650-7 DB - PRIME DP - Unbound Medicine ER -